Nexalin Technology (NXL) Shareholder's Equity Growth (1y) (2022 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Nexalin Technology | 11.19 Mn | 8.48 Mn | 13,133.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.12% |
| Dec 31, 2025 | 1.96% |
| Sep 30, 2025 | -3.82% |
| Jun 30, 2025 | 341.40% |
| Mar 31, 2025 | -0.07% |
| Dec 31, 2024 | 14.64% |
| Sep 30, 2024 | 53.17% |
| Jun 30, 2024 | -66.17% |
| Mar 31, 2024 | -50.86% |
| Dec 31, 2023 | -41.47% |
| Sep 30, 2023 | -49.07% |
| Jun 30, 2023 | 278.22% |
| Mar 31, 2023 | 340.04% |
| Dec 31, 2022 | 425.74% |
| Sep 30, 2022 | 422.84% |